Comparative Pharmacology
Head-to-head clinical analysis: LAMPIT versus METUBINE IODIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMPIT versus METUBINE IODIDE.
LAMPIT vs METUBINE IODIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the enzyme G6PD (glucose-6-phosphate dehydrogenase) in Trypanosoma cruzi, leading to oxidative stress and parasite death.
Nondepolarizing neuromuscular blocking agent; competitively binds to nicotinic acetylcholine receptors at the motor endplate, preventing acetylcholine from inducing depolarization and muscle contraction.
Nifurtimox (Lampit) for Chagas disease: adult dose 8-10 mg/kg/day orally in 3 divided doses for 90 days. For Chagas disease in children: 15-20 mg/kg/day orally in 3 divided doses for 90 days.
0.1-0.3 mg/kg IV as a single dose for neuromuscular blockade during surgery. Additional doses of 0.03-0.05 mg/kg at 25-30 minute intervals as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours. In hepatic impairment, half-life may be prolonged by up to 2-fold.
Terminal elimination half-life: approximately 2-3 minutes (due to rapid redistribution from plasma to tissues), with a longer terminal phase (30-60 minutes) reflecting slow efflux from deep compartments.
Renal excretion of unchanged drug accounts for 10% of the dose; biliary/fecal excretion accounts for approximately 90%, mainly as metabolites.
Primarily renal excretion of unchanged drug (approximately 70-80% over 24 hours); biliary/fecal excretion accounts for <10%.
Category C
Category C
Antiprotozoal
Antiprotozoal